One of the most dangerous and expensive side effects of diabetes is diabetic foot ulcers (DFUs), which can result in extended hospital stays, infections, and, in extreme situations, amputation. Chronic wounds, such as DFUs, are notoriously hard to heal because of weakened immune responses, neuropathy, and poor circulation. Products derived from human tissue have become increasingly popular in recent years as treatments that aid in wound healing and offer defence against external infections. TheraMend®, a dehydrated amniotic membrane allograft developed by Ponya Therapeutics, a reputable, FDA-registered tissue allograft supplier in Atlanta, is one such product at the forefront of wound care innovation.
Diabetic Foot Ulcers
People with diabetes may develop open sores on the bottoms of their feet, known as diabetic foot ulcers. Up to 25% are estimated to develop diabetic foot ulcers during their lifetimes due to factors like poor nerve function (neuropathy), reduced blood flow to extremities, frequent pressure points and delayed wound healing processes.
DFUs present unique challenges due to our bodies’ inability to regenerate tissue and fight infection effectively, rendering traditional treatments such as debridement, offloading, and infection control ineffective at achieving adequate tissue granulation or closure. Advanced wound care products like TheraMend®, with their biologically active scaffolds that act as natural protective barriers against further injury, provide support to the body as it works to heal DFUs.
What is TheraMend®?
TheraMend® is a human tissue allograft composed of dehydrated amniotic membrane, harvested from prescreened, donated placental tissue and preserved at room temperature to retain its biological and regenerative properties. Amniotic membrane, the innermost layer of the placenta, has long been recognized for its extraordinary biological and regenerative abilities; it naturally contains structural proteins, growth factors, and extracellular matrix components that facilitate wound repair, reduce inflammation, and promote epithelialization.
Ponya Therapeutics uses aseptic techniques designed to preserve its functional components while guaranteeing safety and sterility of amniotic membrane. Tissue is minimally altered, creating a dehydrated patch that serves as an effective protective barrier for both acute and chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, surgical incisions etc.
TheraMend® is designed to provide a natural covering that mimics the function of the placenta, protecting the wound from the external environment while promoting the body’s natural healing processes.
Mechanism of Action and Clinical Benefits
The amniotic membrane serves several key roles in wound healing:
- Protective Barrier – Physical barriers prevent external contaminants and mechanical irritation from reaching wounds, providing essential protection for those with exposed tissue or delicate granulation beds.
- Moisture Balance – Dehydrated amniotic membrane can maintain an ideal moist wound environment that fosters cell migration and epithelialization while protecting from desiccation.
- Bioactive Support – Supports the body’s ability to form new blood vessels and modulate inflammation through natural bioactive factors in amniotic tissue.
- Reduced Scar Formation – The membrane’s anti-inflammatory and anti-fibrotic properties may help minimize excessive scar tissue formation, leading to smoother wound closure.
- Ease of Use – Clinicians appreciate that TheraMend® is available in a ready-to-use dehydrated form, requiring minimal preparation and offering consistent performance in multiple wound types.
FDA-Compliant, Minimally Manipulated, and Ethically Sourced Amniotic Allografts for Wound Healing
Ponya Therapeutics upholds rigorous regulatory and quality standards to ensure that every TheraMend® product is safe, pure, and consistent. The company is registered with the U.S. Food and Drug Administration (FDA) as a tissue establishment under 21 CFR 1271 and undergoes biennial inspections to verify compliance with all regulations governing human cell and tissue-based products (HCT/Ps). TheraMend® is produced following Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) guidelines, supported by a robust FDA-compliant Quality Management System (QMS) emphasizing validation, monitoring, and staff training. Using minimal manipulation techniques, Ponya preserves the amniotic membrane’s natural structural and biochemical integrity, retaining its proteins, growth factors, and extracellular matrix, to deliver maximum therapeutic benefit while maintaining sterility and shelf stability. In accordance with the FDA’s homologous use principle, TheraMend® functions as a protective wound covering, replicating the amniotic membrane’s natural role in the placenta. Ethical sourcing and thorough donor screening from consenting full-term cesarean deliveries, with extensive medical and infectious disease testing, ensure every TheraMend® graft meets the highest standards of safety, quality, and regulatory compliance.
Clinical Applications Beyond DFUs
While diabetic foot ulcers are a primary focus, TheraMend® has demonstrated benefits across a wide spectrum of wound types, including:
- Venous leg ulcers – Chronic wounds stemming from poor venous return
- Pressure ulcers – Injuries caused by prolonged pressure over bony areas
- Burns – Acute thermal injuries requiring protective coverage
- Surgical wounds – Postoperative sites needing reinforcement and reduced inflammation
TheraMend® stands out among competing solutions due to its wide-ranging features, safety profile, and ease of application—qualities that make it an excellent choice for surgeons, podiatrists, and wound care specialists who require evidence-based solutions.
TheraMend® in Clinical Practice
Clinicians have reported increased healing rates, reduced infection risk, and enhanced patient outcomes when including TheraMend® in comprehensive diabetic foot ulcer care protocols. The application typically involves surface cleaning, debridement, and placement of a dehydrated patch over the wound bed, followed by secondary dressing application.
Because TheraMend® is derived from human amniotic tissue, it introduces no synthetic or foreign chemical components, reducing immunogenic reactions and promoting biocompatible healing.
Why Choose Ponya Therapeutics?
As a leading tissue allograft supplier in Atlanta, Ponya Therapeutics exemplifies industry-wide commitment to scientific innovation, regulatory compliance, and patient safety. Our dedication to excellence includes comprehensive quality oversight aligned with GTP, GMP, and FDA standards; rigorous donor screening and tightly controlled processing to ensure product consistency and safety; robust clinical support with evidence-based data, usage guidelines, and technical training; and ethical sourcing that relies exclusively on voluntary, non-harmful placental donations in accordance with medical ethics.
TheraMend® is a proven, reliable barrier for diabetic foot ulcers. It supports the natural healing process while protecting the vulnerable tissue. TheraMend® is a wound dressing that integrates easily into modern protocols. The biological benefits of amniotic tissue are backed up by Ponya Therapeutics’ uncompromising standards of ethics, safety and regulatory compliance. Ponya Therapeutics provides wound care teams with a reliable DFU and complex wound solution. With clinically-oriented support, consistent performance and responsibly-sourced materials, Ponya Therapeutics gives wound care professionals a reliable and trusted option.